Daxocox 15 mg Tablets for Dogs

Pays: Royaume-Uni

Langue: anglais

Source: VMD (Veterinary Medicines Directorate)

Ingrédients actifs:

Enflicoxib

Disponible depuis:

Ecuphar NV

Code ATC:

QM01AH95

DCI (Dénomination commune internationale):

Enflicoxib

forme pharmaceutique:

Tablet

Type d'ordonnance:

POM-V - Prescription Only Medicine – Veterinarian

Groupe thérapeutique:

Dogs

Domaine thérapeutique:

Anti Inflammatory NSAID

Statut de autorisation:

Authorized

Date de l'autorisation:

2021-04-01

Résumé des caractéristiques du produit

Revised: March 2024
AN: 03007/2023
Page 1 of 7
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Daxocox 15 mg tablets for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Enflicoxib
15 mg
EXCIPIENTS:
Iron oxide black (E172) 0.26%
Iron oxide yellow (E172) 0.45%
Iron oxide red (E172) 0.50%
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets
Brown, round and convex tablets.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For
the
treatment
of
pain
and
inflammation
associated
with
osteoarthritis
(or
degenerative joint disease) in dogs.
4.3
CONTRAINDICATIONS
Do not use in animals suffering from gastrointestinal disorders,
protein or blood losing
enteropathy or haemorrhagic disorders.
Do not use in cases of impaired renal or hepatic function.
Do not use in cases of cardiac insufficiency.
Do not use in pregnant or lactating dogs.
Do not use in animals intended for breeding purposes.
Do not use in cases of hypersensitivity to the active substance or to
any of the
excipients.
Revised: March 2024
AN: 03007/2023
Page 2 of 7
Do not use in cases of known hypersensitivity to sulphonamides.
Do not use in any dehydrated, hypovolemic or hypotensive animal, as
there is a
potential risk of increased renal toxicity.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Do
not
administer
other
Non-Steroidal
Anti-Inflammatory
Drugs
(NSAIDs)
or
glucocorticoids concurrently or within 2 weeks of the last
administration of this
veterinary medicinal product.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Since the safety of the medicinal product has not been fully
demonstrated in very young
animals, careful monitoring is advised during the treatment of young
dogs aged less
than 6 months.
The active metabolite of enflicoxib exhibits an extended plasma
half-life due to its low
rate of elimination. Use this veterinary medicinal product under
strict veterinary
monitoring where t